Abstract
Background: No definitive comparisons of surgical morbidity between segmentectomy and lobectomy for non–small cell lung cancer have been reported. Methods: We conducted a randomized controlled trial to confirm the noninferiority of segmentectomy to lobectomy in regard to prognosis (trial No. JCOG0802/WJOG4607L). Patients with invasive peripheral non–small cell lung cancer tumor of a diameter ≤2 cm were randomized to undergo either lobectomy or segmentectomy. The primary end point was overall survival. Here, we have focused on morbidity and mortality. Predictors of surgical morbidity were evaluated by the mode of surgery. Segmentectomy was categorized into simple and complex. Simple segmentectomy was defined as segmental resection of the right or left segment 6, left superior, or lingular segment. Complex segmentectomy was resection of the other segment. This trial is registered with the University Hospital Medical Information Network–Clinical Trial Registry (UMIN000002317). Results: Between August 10, 2009, and October 21, 2014, 1106 patients (lobectomy n = 554 and segmentectomy n = 552) were enrolled. No mortality was noted. Complications (grade ≥ 2) occurred in 26.2% and 27.4% in the lobectomy and segmentectomy arms (P =.68), respectively. Fistula/pulmonary-lung (air leak) was detected in 21 (3.8%) and 36 (6.5%) patients in the lobectomy and segmentectomy arms (P =.04), respectively. Multivariable analysis revealed that predictors of pulmonary complications, including air leak and empyema (grade ≥ 2) were complex segmentectomy (vs lobectomy) (odds ratio, 2.07; 95% confidence interval, 1.11-3.88; P =.023), and > 20 pack-years of smoking (odds ratio, 2.61; 95% confidence interval, 1.14-5.97; P =.023). Conclusions: There was no difference in almost any postoperative measure of intraoperative and postoperative complication in segmentectomy and lobectomy patients, except more air leakage was observed in the segmentectomy arm. Segmentectomy will be a standard treatment if the superior pulmonary function and noninferiority in overall survival are confirmed.
Original language | English |
---|---|
Pages (from-to) | 895-907 |
Number of pages | 13 |
Journal | Journal of Thoracic and Cardiovascular Surgery |
Volume | 158 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2019 Sept |
Keywords
- complex segmentectomy
- intentional sublobar resection
- morbidity
- prognosis
ASJC Scopus subject areas
- Surgery
- Pulmonary and Respiratory Medicine
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Thoracic and Cardiovascular Surgery, Vol. 158, No. 3, 09.2019, p. 895-907.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Comparison of pulmonary segmentectomy and lobectomy
T2 - Safety results of a randomized trial
AU - West Japan Oncology Group
AU - Japan Clinical Oncology Group
AU - Suzuki, Kenji
AU - Saji, Hisashi
AU - Aokage, Keiju
AU - Watanabe, Shun ichi
AU - Okada, Morihito
AU - Mizusawa, Junki
AU - Nakajima, Ryu
AU - Tsuboi, Masahiro
AU - Nakamura, Shinichiro
AU - Nakamura, Kenichi
AU - Mitsudomi, Tetsuya
AU - Asamura, Hisao
N1 - Funding Information: Supported by the National Cancer Center, Ministry of Health,Labour and Welfare of Japan as well as grants from the Japan Agency for Medical Research and Development (Dr Mizusawa).Dr Suzuki reports grants and personal fees from Ethicon, Medtronic, Taiho, Eli Lilly, Kyowa Kirin, Teijin, and CSL Behring; personal fees from Intutive, Daiichi Sankyo, Gunze, AstraZeneca, and The Chemo-Sero-Therapeutic Research Institute; and grants from Shoen kai, Ezai, Shionogi, and Ono outside this work. Dr Saji reports personal fees from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Nihon Medi-Physics, Pfizer, Ethicon, Chugai Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, and FujiFilm Medical Co Ltd outside this work. Dr Aokage reports personal fees from Covidien Japan (seminar presentations and editorial supervision), Johnson & Johnson (interview on product development, video presentation, and seminar presentation), Taiho Pharma (writing), Teijin Pharma (seminar presentation), CSL Behring (writing and editorial supervision), Sano Hospital (surgical supervision), Uchio Clinic (medical supervision), Medela Healthcare (seminar presentation), Yokohama City University Medical Center (seminar presentation), and Konica Minolta (medical supervision)outside this work. Dr Watanabe reports personal fees from Ethicon Endo-Surgery Japan, a Johnson & Johnson company; Covidien Japan; CSL Behring; Astellas; and Stryker outside this work. Dr Okada reports grants and personal fees from Astellas Pharma Inc, AstraZeneca Plc, Eisai Co Ltd, Merck Sharp & Dohme, Otsuka Pharmaceutical Company Ltd, Ono Pharmaceutical Company Ltd, Kyowa Hakko Kirin Company Ltd, Medtronic, Sanofi SA, Daiichi Sankyo Company Ltd, Shionogi & Company Ltd, Shimadzu Corporation, Johnson & Johnson, CSL Behring KK, Taiho Pharmaceutical Company Ltd, Chugai Ro Company Ltd, Takeda Pharmaceutical Company Ltd, Tsumura & Company, Eli Lilly and Company, Nippon Kayaku Company Ltd, Boehringer Ingelheim GmbH, Nihon Pharmaceutical Company Ltd, Nihon Medi-Physics Company Ltd, Novartis Pharma KK, Pfizer Inc, Fuji Pharma Company Ltd, Bristol-Myers Squibb, Mochida Pharmaceutical Company Ltd, and Yakult Honsha Company Ltd outside this work. Dr Mizusawa reports personal fees from Chugai Pharmaceutical outside this work. Dr Tsuboi reports grants from AstraZeneca KK as well as personal fees from AstraZeneca KK, Eli Lilly Japan, Boehringer-Ingelheim Japan, Daiichi-Sankyo, Chugai Pharmaceutical Company Ltd, Taiho Pharma, Johnson & Johnson Japan, Covidien Japan, Teijin Pharma, CSL Behring, Bristol-Myers Squibb Japan, and MSD Japan outside this work. Dr K. Nakamura reports personal fees from Taiho, Merck, Chugai, and Bayer outside this work. Dr Mitsudomi reports personal fees from AstraZeneca, MSD, BMS, Daiichi-Sankyo, Kyowa-Hakko Kirin, and Johnson & Johnson as well as grants and personal fees from Pfizer, Boehringer Ingelheim, Ono, Taiho, Eli Lilly, Chugai, and Covidien outside this work. Dr Asamura reports personal fees from Covidien Japan, Johnson & Johnson, Shionogi Pharma, AstraZeneca, Novartis, Astellas Pharma, Taiho Pharmaceutical, Kyowa Kirin, Ono Pharma, Eli Lilly, and Chugai outside this work. All other authors have nothing to disclose with regard to commercial support. Participating institutions (from north to south): Japan Clinical Oncology Group, Sendai Medical Center, Tohoku University Hospital, Iwaki Kyoritsu Hospital, Ibaragi Prefectural Central Hospital, Tochigi Cancer Center, Gunma Cancer Center, Saitama Cancer Center, National Cancer Center Hospital East, Chiba University Hospital, National Cancer Center Hospital, Tokyo Medical University Hospital, Cancer Institute Hospital, Juntendo University Hospital, Kanagawa Cancer Center, Niigata Cancer Center, Kanazawa University Hospital, Saku Central Hospital, Shizuoka Cancer Center, Aichi Cancer Center, Kyoto University Hospital, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Kinki-chuo Chest Medical Center, Osaka City General Hospital, Hyogo Cancer Center, Okayama University Hospital, Hiroshima University Hospital, Kure Medical Center, Shikoku Cancer Center, Kyushu Cancer Center, Fukuoka University Hospital, Nagasaki University Hospital, Kumamoto Chuo Hospital, and Okinawa National Hospital. West Japan Oncology Group, Kitasato University Hospital, Kanagawa Cardiovascular and Respiratory Center, Sagamihara Kyodo Hospital, Toyama University Hospital, Ishikawa Prefectural Central Hospital, Gifu City Hospital, Hamamatsu Medical University Hospital, Serie Hamamatsu General Hospital, Aichi Cancer Center Aichi Hospital, Nagoya Medical Center, Nagoya University Hospital, Nagoya Elishia Hospital, Shiga University of Medical Science Hospital, Osaka University Hospital, Osaka City University Hospital, Kinki University Hospital, National Tone Yama Hospital, Rinku General Medical Center, Suita Municipal Hospital, Kobe University Hospital, Kobe City Medical Center General Hospital, Hyogo Medical College University, Hyogo Prefectural Awaji Hospital, Himeji Red Cross Hospital, Kurashiki Central Hospital, Kawasaki Medical School Hospital, Hiroshima City Hospital, Hiroshima City Asa Hospital, Yamaguchi Ube Medical Center, University of Occupational and Environmental Health, Nippon Steel Yazata Memorial Hospital, Iizuka Hospital, Saga University Hospital, Kumamoto University Hospital, Kumamoto Regional Medical Center, Saiseikai Kumamoto Hospital, and Oita Prefectural Hospital. Funding Information: Supported by the National Cancer Center , Ministry of Health,Labour and Welfare of Japan as well as grants from the Japan Agency for Medical Research and Development (Dr Mizusawa). Funding Information: Supported by the National Cancer Center, Ministry of Health,Labour and Welfare of Japan as well as grants from the Japan Agency for Medical Research and Development (Dr Mizusawa).Dr Suzuki reports grants and personal fees from Ethicon, Medtronic, Taiho, Eli Lilly, Kyowa Kirin, Teijin, and CSL Behring; personal fees from Intutive, Daiichi Sankyo, Gunze, AstraZeneca, and The Chemo-Sero-Therapeutic Research Institute; and grants from Shoen kai, Ezai, Shionogi, and Ono outside this work. Dr Saji reports personal fees from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Nihon Medi-Physics, Pfizer, Ethicon, Chugai Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, and FujiFilm Medical Co Ltd outside this work. Dr Aokage reports personal fees from Covidien Japan (seminar presentations and editorial supervision), Johnson & Johnson (interview on product development, video presentation, and seminar presentation), Taiho Pharma (writing), Teijin Pharma (seminar presentation), CSL Behring (writing and editorial supervision), Sano Hospital (surgical supervision), Uchio Clinic (medical supervision), Medela Healthcare (seminar presentation), Yokohama City University Medical Center (seminar presentation), and Konica Minolta (medical supervision) outside this work. Dr Watanabe reports personal fees from Ethicon Endo-Surgery Japan, a Johnson & Johnson company; Covidien Japan; CSL Behring; Astellas; and Stryker outside this work. Dr Okada reports grants and personal fees from Astellas Pharma Inc, AstraZeneca Plc, Eisai Co Ltd, Merck Sharp & Dohme, Otsuka Pharmaceutical Company Ltd, Ono Pharmaceutical Company Ltd, Kyowa Hakko Kirin Company Ltd, Medtronic, Sanofi SA, Daiichi Sankyo Company Ltd, Shionogi & Company Ltd, Shimadzu Corporation, Johnson & Johnson, CSL Behring KK, Taiho Pharmaceutical Company Ltd, Chugai Ro Company Ltd, Takeda Pharmaceutical Company Ltd, Tsumura & Company, Eli Lilly and Company, Nippon Kayaku Company Ltd, Boehringer Ingelheim GmbH, Nihon Pharmaceutical Company Ltd, Nihon Medi-Physics Company Ltd, Novartis Pharma KK, Pfizer Inc, Fuji Pharma Company Ltd, Bristol-Myers Squibb, Mochida Pharmaceutical Company Ltd, and Yakult Honsha Company Ltd outside this work. Dr Mizusawa reports personal fees from Chugai Pharmaceutical outside this work. Dr Tsuboi reports grants from AstraZeneca KK as well as personal fees from AstraZeneca KK, Eli Lilly Japan, Boehringer-Ingelheim Japan, Daiichi-Sankyo, Chugai Pharmaceutical Company Ltd, Taiho Pharma, Johnson & Johnson Japan, Covidien Japan, Teijin Pharma, CSL Behring, Bristol-Myers Squibb Japan, and MSD Japan outside this work. Dr K. Nakamura reports personal fees from Taiho, Merck, Chugai, and Bayer outside this work. Dr Mitsudomi reports personal fees from AstraZeneca, MSD, BMS, Daiichi-Sankyo, Kyowa-Hakko Kirin, and Johnson & Johnson as well as grants and personal fees from Pfizer, Boehringer Ingelheim, Ono, Taiho, Eli Lilly, Chugai, and Covidien outside this work. Dr Asamura reports personal fees from Covidien Japan, Johnson & Johnson, Shionogi Pharma, AstraZeneca, Novartis, Astellas Pharma, Taiho Pharmaceutical, Kyowa Kirin, Ono Pharma, Eli Lilly, and Chugai outside this work. All other authors have nothing to disclose with regard to commercial support. Participating institutions (from north to south):, Japan Clinical Oncology Group, Sendai Medical Center, Tohoku University Hospital, Iwaki Kyoritsu Hospital, Ibaragi Prefectural Central Hospital, Tochigi Cancer Center, Gunma Cancer Center, Saitama Cancer Center, National Cancer Center Hospital East, Chiba University Hospital, National Cancer Center Hospital, Kyorin University Hospital, Tokyo Medical University Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Cancer Institute Hospital, Juntendo University Hospital, St. Marianna University School of Medicine, Kanagawa Cancer Center, Yokohama Municipal Citizen's Hospital, Yokohama City University Medical Center, Niigata Cancer Center, Kanazawa University Hospital, Saku Central Hospital, Shizuoka Cancer Center, Aichi Cancer Center, Nagoya University Hospital, Kyoto University Hospital, Osaka University Hospital, Kindai University Faculty of Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka City General Hospital, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Kinki-chuo Chest Medical Center, Osaka City General Hospital, Hyogo Cancer Center, Kurashiki Central Hospital, Okayama University Hospital, Hiroshima University Hospital, Kure Medical Center, Shikoku Cancer Center, Kyushu Cancer Center, Fukuoka University Hospital, Nagasaki University Hospital, Kumamoto University Hospital, Kumamoto Chuo Hospital, Oita University Hospital, and Okinawa National Hospital. West Japan Oncology Group, Kitasato University Hospital, Kanagawa Cardiovascular and Respiratory Center, Sagamihara Kyodo Hospital, Toyama University Hospital, Ishikawa Prefectural Central Hospital, Gifu City Hospital, Hamamatsu Medical University Hospital, Serie Hamamatsu General Hospital, Aichi Cancer Center Aichi Hospital, Nagoya Medical Center, Nagoya University Hospital, Nagoya Elishia Hospital, Shiga University of Medical Science Hospital, Osaka University Hospital, Osaka City University Hospital, Kinki University Hospital, National Tone Yama Hospital, Rinku General Medical Center, Suita Municipal Hospital, Kobe University Hospital, Kobe City Medical Center General Hospital, Hyogo Medical College University, Hyogo Prefectural Awaji Hospital, Himeji Red Cross Hospital, Kawasaki Medical School Hospital, Hiroshima City Hospital, Hiroshima City Asa Hospital, Yamaguchi Ube Medical Center, University of Occupational and Environmental Health, Nippon Steel Yazata Memorial Hospital, Iizuka Hospital, Saga University Hospital, Kumamoto University Hospital, Kumamoto Regional Medical Center, Saiseikai Kumamoto Hospital, and Oita Prefectural Hospital. Funding Information: Dr Suzuki reports grants and personal fees from Ethicon , Medtronic , Taiho , Eli Lilly , Kyowa Kirin , Teijin , and CSL Behring ; personal fees from Intutive, Daiichi Sankyo, Gunze, AstraZeneca, and The Chemo-Sero-Therapeutic Research Institute; and grants from Shoen kai , Ezai , Shionogi , and Ono outside this work. Dr Saji reports personal fees from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Nihon Medi-Physics, Pfizer, Ethicon, Chugai Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, and FujiFilm Medical Co Ltd outside this work. Dr Aokage reports personal fees from Covidien Japan (seminar presentations and editorial supervision), Johnson & Johnson (interview on product development, video presentation, and seminar presentation), Taiho Pharma (writing), Teijin Pharma (seminar presentation), CSL Behring (writing and editorial supervision), Sano Hospital (surgical supervision), Uchio Clinic (medical supervision), Medela Healthcare (seminar presentation), Yokohama City University Medical Center (seminar presentation), and Konica Minolta (medical supervision) outside this work. Dr Watanabe reports personal fees from Ethicon Endo-Surgery Japan, a Johnson & Johnson company; Covidien Japan; CSL Behring; Astellas; and Stryker outside this work. Dr Okada reports grants and personal fees from Astellas Pharma Inc, AstraZeneca Plc, Eisai Co Ltd, Merck Sharp & Dohme , Otsuka Pharmaceutical Company Ltd, Ono Pharmaceutical Company Ltd, Kyowa Hakko Kirin Company Ltd, Medtronic , Sanofi SA, Daiichi Sankyo Company Ltd, Shionogi & Company Ltd, Shimadzu Corporation , Johnson & Johnson , CSL Behring KK , Taiho Pharmaceutical Company Ltd, Chugai Ro Company Ltd, Takeda Pharmaceutical Company Ltd, Tsumura & Company, Eli Lilly and Company , Nippon Kayaku Company Ltd , Boehringer Ingelheim GmbH, Nihon Pharmaceutical Company Ltd , Nihon Medi-Physics Company Ltd , Novartis Pharma KK , Pfizer Inc, Fuji Pharma Company Ltd , Bristol-Myers Squibb , Mochida Pharmaceutical Company Ltd, and Yakult Honsha Company Ltd outside this work. Dr Mizusawa reports personal fees from Chugai Pharmaceutical outside this work. Dr Tsuboi reports grants from AstraZeneca KK as well as personal fees from AstraZeneca KK , Eli Lilly Japan , Boehringer-Ingelheim Japan, Daiichi-Sankyo , Chugai Pharmaceutical Company Ltd, Taiho Pharma , Johnson & Johnson Japan, Covidien Japan, Teijin Pharma , CSL Behring , Bristol-Myers Squibb Japan, and MSD Japan outside this work. Dr K. Nakamura reports personal fees from Taiho, Merck, Chugai, and Bayer outside this work. Dr Mitsudomi reports personal fees from AstraZeneca, MSD, BMS, Daiichi-Sankyo, Kyowa-Hakko Kirin, and Johnson & Johnson as well as grants and personal fees from Pfizer , Boehringer Ingelheim , Ono , Taiho , Eli Lilly , Chugai , and Covidien outside this work. Dr Asamura reports personal fees from Covidien Japan, Johnson & Johnson, Shionogi Pharma, AstraZeneca, Novartis, Astellas Pharma, Taiho Pharmaceutical, Kyowa Kirin, Ono Pharma, Eli Lilly, and Chugai outside this work. All other authors have nothing to disclose with regard to commercial support. Publisher Copyright: © 2019 The American Association for Thoracic Surgery
PY - 2019/9
Y1 - 2019/9
N2 - Background: No definitive comparisons of surgical morbidity between segmentectomy and lobectomy for non–small cell lung cancer have been reported. Methods: We conducted a randomized controlled trial to confirm the noninferiority of segmentectomy to lobectomy in regard to prognosis (trial No. JCOG0802/WJOG4607L). Patients with invasive peripheral non–small cell lung cancer tumor of a diameter ≤2 cm were randomized to undergo either lobectomy or segmentectomy. The primary end point was overall survival. Here, we have focused on morbidity and mortality. Predictors of surgical morbidity were evaluated by the mode of surgery. Segmentectomy was categorized into simple and complex. Simple segmentectomy was defined as segmental resection of the right or left segment 6, left superior, or lingular segment. Complex segmentectomy was resection of the other segment. This trial is registered with the University Hospital Medical Information Network–Clinical Trial Registry (UMIN000002317). Results: Between August 10, 2009, and October 21, 2014, 1106 patients (lobectomy n = 554 and segmentectomy n = 552) were enrolled. No mortality was noted. Complications (grade ≥ 2) occurred in 26.2% and 27.4% in the lobectomy and segmentectomy arms (P =.68), respectively. Fistula/pulmonary-lung (air leak) was detected in 21 (3.8%) and 36 (6.5%) patients in the lobectomy and segmentectomy arms (P =.04), respectively. Multivariable analysis revealed that predictors of pulmonary complications, including air leak and empyema (grade ≥ 2) were complex segmentectomy (vs lobectomy) (odds ratio, 2.07; 95% confidence interval, 1.11-3.88; P =.023), and > 20 pack-years of smoking (odds ratio, 2.61; 95% confidence interval, 1.14-5.97; P =.023). Conclusions: There was no difference in almost any postoperative measure of intraoperative and postoperative complication in segmentectomy and lobectomy patients, except more air leakage was observed in the segmentectomy arm. Segmentectomy will be a standard treatment if the superior pulmonary function and noninferiority in overall survival are confirmed.
AB - Background: No definitive comparisons of surgical morbidity between segmentectomy and lobectomy for non–small cell lung cancer have been reported. Methods: We conducted a randomized controlled trial to confirm the noninferiority of segmentectomy to lobectomy in regard to prognosis (trial No. JCOG0802/WJOG4607L). Patients with invasive peripheral non–small cell lung cancer tumor of a diameter ≤2 cm were randomized to undergo either lobectomy or segmentectomy. The primary end point was overall survival. Here, we have focused on morbidity and mortality. Predictors of surgical morbidity were evaluated by the mode of surgery. Segmentectomy was categorized into simple and complex. Simple segmentectomy was defined as segmental resection of the right or left segment 6, left superior, or lingular segment. Complex segmentectomy was resection of the other segment. This trial is registered with the University Hospital Medical Information Network–Clinical Trial Registry (UMIN000002317). Results: Between August 10, 2009, and October 21, 2014, 1106 patients (lobectomy n = 554 and segmentectomy n = 552) were enrolled. No mortality was noted. Complications (grade ≥ 2) occurred in 26.2% and 27.4% in the lobectomy and segmentectomy arms (P =.68), respectively. Fistula/pulmonary-lung (air leak) was detected in 21 (3.8%) and 36 (6.5%) patients in the lobectomy and segmentectomy arms (P =.04), respectively. Multivariable analysis revealed that predictors of pulmonary complications, including air leak and empyema (grade ≥ 2) were complex segmentectomy (vs lobectomy) (odds ratio, 2.07; 95% confidence interval, 1.11-3.88; P =.023), and > 20 pack-years of smoking (odds ratio, 2.61; 95% confidence interval, 1.14-5.97; P =.023). Conclusions: There was no difference in almost any postoperative measure of intraoperative and postoperative complication in segmentectomy and lobectomy patients, except more air leakage was observed in the segmentectomy arm. Segmentectomy will be a standard treatment if the superior pulmonary function and noninferiority in overall survival are confirmed.
KW - complex segmentectomy
KW - intentional sublobar resection
KW - morbidity
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=85065164811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065164811&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2019.03.090
DO - 10.1016/j.jtcvs.2019.03.090
M3 - Article
C2 - 31078312
AN - SCOPUS:85065164811
SN - 0022-5223
VL - 158
SP - 895
EP - 907
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 3
ER -